

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, JAPAN, AUSTRALIA OR ANY COUNTRY WHERE IT IS UNLAWFUL TO DO SO.

This announcement is an advertisement and not a prospectus and not an offer of securities for sale in or into the United States, Canada, Japan or Australia, or any other jurisdiction where it is unlawful to do so.

COMUNICATO STAMPA

IPO PHILOGEN: RISULTATI DEFINITIVI DEL COLLOCAMENTO ISTITUZIONALE

- **Concluso con successo il Collocamento Istituzionale di azioni Philogen, con una domanda complessiva maggiore di Euro 210 milioni**
- **Prezzo di Offerta pari a Euro 17 per azione e capitalizzazione della Società pari a Euro 690 milioni**
- **Inizio delle negoziazioni previsto in data 3 marzo 2021**

Siena, 1 marzo 2021 - Philogen S.p.A. (“**Philogen**” o la “**Società**”) rende noto che si è conclusa con successo l’offerta globale di sottoscrizione delle azioni ordinarie della Società (le “**Azioni**”) riservata a investitori istituzionali (il “**Collocamento Istituzionale**”) finalizzata alla quotazione sul Mercato Telematico Azionario, organizzato e gestito da Borsa italiana S.p.A. (“**MTA**”), con una domanda complessiva che, al prezzo di offerta, ha superato i 210 milioni di euro.

La domanda istituzionale è pervenuta da primari investitori esteri ed italiani con un’ampia diversificazione geografica che comprende Regno Unito, Stati Uniti d’America, Italia ed Europa Continentale.

In base alle richieste pervenute nell’ambito del Collocamento Istituzionale, sono state assegnate n. 4.467.222 Azioni, e in particolare (i) n. 4.061.111 Azioni derivanti da un aumento di capitale con esclusione del diritto di opzione (l’**Aumento di Capitale**”), corrispondenti al 10% circa del capitale sociale della Società *post* Aumento di Capitale; e (ii) n. 406.111 Azioni sottostanti all’opzione *over-allotment* concesse in prestito da parte degli azionisti Nerbio S.r.l. e Dompé Holdings S.r.l. ai *joint global coordinators*, corrispondenti ad un ulteriore 1% circa del capitale sociale di Philogen, *post* Aumento di Capitale. Pertanto, tenuto conto del corrente grado di diffusione dell’azionariato di Philogen, il numero di Azioni complessivamente detenute dal mercato ad esito del Collocamento istituzionale sarà adeguato rispetto al minimo requisito richiesto da Borsa Italiana per il Mercato Telematico Azionario.

Il prezzo di offerta delle Azioni è stato fissato in Euro 17 per Azione (il “**Prezzo di Offerta**”). In base al Prezzo di Offerta, la capitalizzazione della Società alla data di avvio delle negoziazioni sarà pari a Euro 690 milioni.

Il ricavato complessivo derivante dal Collocamento Istituzionale, riferito al Prezzo di Offerta, senza tenere conto dell’assegnazione delle azioni sottostanti all’opzione *over-allotment*, è pari a Euro 69 milioni, spettanti alla Società, mentre, il ricavato complessivo, ivi inclusi i proventi spettanti agli azionisti Nerbio S.r.l. e Dompé Holdings S.r.l. per l’assegnazione delle azioni sottostanti all’opzione *over-allotment*, è pari ad Euro 76 milioni.

La data di inizio delle negoziazioni delle Azioni sul MTA e quella di pagamento delle stesse sono previste per il 3 marzo 2021.

Nell'ambito dell'offerta, Goldman Sachs International e Mediobanca – Banca di Credito Finanziario S.p.A. agiscono in qualità di *joint global coordinators* e *joint bookrunners*, mentre Stifel Europe Bank AG – Milan Branch agisce in qualità di *co-bookrunner*. Mediobanca - Banca di Credito Finanziario S.p.A. agisce altresì in qualità di *Sponsor* per l'ammissione a quotazione delle Azioni sul MTA.

White & Case agisce in qualità di consulente legale della Società, mentre Linklaters agisce in qualità di consulente legale dei *joint global coordinators* e *joint bookrunners* e del *co-bookrunner*. La società incaricata della revisione legale dei conti di Philogen è KPMG S.p.A..

Philogen è un'azienda italo-svizzera attiva nel settore delle biotecnologie, specializzata nella ricerca e sviluppo di prodotti farmaceutici per il trattamento di patologie ad alto tasso di letalità. Di fatto, il Gruppo scopre e sviluppa principalmente farmaci antitumorali mirati, sfruttando ligandi ad alta affinità per *markers* tumorali (chiamati anche antigeni tumorali). Questi ligandi - anticorpi monoclonali umani o piccole molecole organiche - vengono identificati tramite le tecnologie di *Antibody Phage Display Libraries* e *DNA-Encoded Chemical Libraries*.

La principale strategia terapeutica del Gruppo per il trattamento di tali patologie è rappresentata dal c.d. *tumor targeting*. Questo approccio si basa sull'uso di ligandi capaci di veicolare in maniera selettiva principi attivi terapeutici molto potenti (come ad esempio citochine pro-infiammatorie) presso la massa tumorale, risparmiando i tessuti sani. Nel corso degli anni Philogen ha principalmente sviluppato ligandi a base di anticorpi monoclonali, specifici per antigeni espressi nei vasi sanguigni associati ai tumori, ma non espressi nei vasi sanguigni associati ai tessuti sani. Questi antigeni sono solitamente più abbondanti e più stabili rispetto a quelli espressi direttamente sulla superficie delle cellule tumorali. Questo approccio, c.d. *vascular targeting*, è utilizzato per la maggior parte dei progetti perseguiti dal Gruppo.

L'obiettivo del Gruppo è quello di generare, sviluppare e commercializzare prodotti innovativi per il trattamento di malattie per le quali la scienza medica non ha ancora individuato terapie soddisfacenti. Ciò è possibile sfruttando (i) le tecnologie proprietarie per l'isolamento di ligandi che reagiscono con antigeni presenti in determinate patologie, (ii) l'esperienza nello sviluppo di prodotti mirati ai tessuti interessati dalla patologia, (iii) l'esperienza nella produzione e nello sviluppo di farmaci e (iv) l'ampio portafoglio di brevetti e diritti di proprietà intellettuale.

Nonostante i farmaci del Gruppo siano principalmente applicazioni oncologiche, l'approccio di targeting è potenzialmente applicabile anche ad altre patologie, quali alcune malattie infiammatorie croniche.

PER ULTERIORI INFORMAZIONI:

Philogen - Investor Relations

IR@philogen.com - Emanuele Puca | *Investor Relator*

DISCLAIMER

This document is an announcement and not a prospectus for the purposes of Regulation (EU) 2017/1129 (the "**Prospectus Regulation**"), and as such does not constitute an offer to sell or the solicitation of an offer to purchase securities. A prospectus prepared pursuant to the Prospectus Regulation, Commission Delegated Regulation (EU) 2019/980, the Commission Delegated Regulation (EU) 2019/979 (the "**Delegated Regulations**"), Legislative Decree n. 58/1998 of 24 February 1998, as subsequently amended (the "**Consolidated Financial Law**") and Regulation adopted by CONSOB with Resolution no. 11971 of 14 May 1999, as subsequently amended (the "**Issuers' Regulation**"), is expected to be approved by the Consob and be made available in accordance with the requirements of the Prospectus Regulation, the Delegated Regulations, the Consolidated Financial Law and the Issuers' Regulation. Any offer of securities to the public that may be deemed to be made pursuant to this communication in any EU Member State is addressed solely to qualified investors (within the meaning of Article 2(1)(e) of the Prospectus Regulation) in that Member State.

This announcement does not constitute or form part of any offer or invitation to sell or issue, or any solicitation of any offer to purchase or subscribe for any shares or any other securities, nor shall it (or any part of it) or the fact of its distribution form the basis of, or be relied on in connection with, any contract therefor. The Offering and the distribution of this announcement and other information in connection with the Offering in certain jurisdictions may be restricted by law and persons into whose possession this announcement or any document or other information referred to herein comes should inform themselves about, and observe, any such restrictions. Any failure to comply with these restrictions may constitute a violation of the laws of any such jurisdiction.

This communication is directed only at (i) persons who are outside the United Kingdom or (ii) persons who have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "Order") and (iii) high net worth entities, and other persons to whom it may lawfully be communicated, falling within Article 49(2) of the Order or (iv) certified high net worth individuals and certified and self-certified sophisticated investors as described in Articles 48, 50, and 50A respectively of the Order or (v) persons to whom this communication may otherwise be lawfully communicated (all such persons together being referred to as "relevant persons"). Any investment activity to which this communication relates will only be available to and will only be engaged in with, relevant persons. Any person who is not a relevant person should not act or rely on this document or any of its contents.

Neither this announcement, nor any copy of it may be taken, transmitted or distributed, directly or indirectly, into Australia, Canada, Japan, or to any persons in any of those jurisdictions or any other jurisdictions where to do so would constitute a violation of the laws of such jurisdiction. The securities referred to herein have not been and will not be qualified under the applicable securities laws of Australia, Canada, Japan and, subject to certain exceptions, may not be offered or sold within Australia, Canada, Japan or to any resident or citizen of Australia, Canada, Japan.

This announcement does not constitute an offer for sale of, or a solicitation of an offer to purchase or subscribe for, any securities in the United States. No securities of the Company have been registered under the U.S. Securities Act of 1933, as amended, and the Company does not intend to register any of the securities in the United States or to conduct a public offering of the securities in the United States. There will be no public offering of the securities in the United States or elsewhere.

This announcement does not constitute a recommendation concerning the Offering or the shares of the Company. The price and value of securities can go down as well as up. Past performance is not a guide to future performance. Information in this announcement or any of the documents relating to the Offering cannot be relied upon as a guide to future performance. Potential investors should consult, to the extent they deem necessary, a professional investment, business, tax, and/or legal advisor as to the suitability of the Offering for the person concerned.

Any purchase of shares of the Company in the proposed Offering should be made solely on the basis of the information contained in the Prospectus, as approved by Consob, to be issued by the Company in connection with the admission to trading on the MTA. The approval of the Prospectus by Consob shall not constitute an evaluation of the economic and financial soundness of the transaction and the quality or solvency of the Company. No reliance may or should be placed by any person for any purpose whatsoever on the information contained in this announcement or on its completeness, accuracy or fairness. The information in this announcement is subject to change.

Certain figures contained in this document, including financial information, have been subject to rounding adjustments. Accordingly, in certain instances, the sum or percentage change of the numbers contained in this document may not conform exactly with the total figure given.

None of the banks acting as joint global coordinators, joint bookrunners and/or co-bookrunner in the contest of the potential initial public offering (the “**Managers**”) or any of their respective directors, officers, employees, advisers or agents accepts any responsibility or liability whatsoever for or makes any representation or warranty, express or implied, as to the truth, accuracy or completeness of the information in this announcement (or whether any information has been omitted from the announcement) or any other information relating to the Company, its subsidiaries or associated companies, whether written, oral or in a visual or electronic form, and howsoever transmitted or made available or for any loss howsoever arising from any use of this announcement or its contents or otherwise arising in connection therewith. Nothing contained herein is, or shall be relied upon as, a promise or representation by the Managers or any of their respective directors, officers, employees, advisers or agents in this respect, whether as to the past or future.

None of the Managers or any of their respective directors, officers, employees, advisers or agents assumes any responsibility for its accuracy, completeness or verification and accordingly the Managers and each of their respective directors, officers, employees, advisers or agents disclaim, to the fullest extent permitted by applicable law, any and all liability whether arising in tort, contract or otherwise which they might otherwise be found to have in respect of this announcement or any such statement. The Managers are each acting exclusively for the Company and the Selling Shareholder in the transaction referred to in this announcement and for no-one else in connection with any transaction mentioned in this announcement and will not regard any other person (whether or not a recipient of this announcement) as a client in relation to any such transaction and will not be responsible to any other person for providing the protections afforded to their respective clients, or for advising any such person on the contents of this announcement or in connection with any transaction referred to in this announcement.

Solely for the purposes of the product governance requirements contained within: (a) EU Directive 2014/65/EU on markets in financial instruments, as amended (“MiFID II”); (b) Articles 9 and 10 of Commission Delegated Directive (EU) 2017/593 supplementing MiFID II; and (c) local implementing measures (together, the “MiFID II Product Governance Requirements”), (d) Regulation (EU) No 600/2014 as it forms part of United Kingdom domestic law by virtue of the EUWA (“UK MiFIR”); and (e) the FCA Handbook Product Intervention and Product Governance Sourcebook (together, the “Product Governance Requirements”), and disclaiming all and any liability, whether arising in tort, contract or otherwise, which any “manufacturer” (for the purposes of the Product Governance Requirements) may otherwise have with respect thereto, the Shares have been subject to a product approval process, which has determined that: (i) the target market for the Shares (a) in the EEA, eligible counterparties and professional clients only, each as defined in MiFID II; and (b) in the United Kingdom, eligible counterparties (as defined in the FCA Handbook Conduct of Business Sourcebook) and professional clients (as defined in UK MiFIR); and (ii) all channels for distribution of the Shares to eligible counterparties and professional clients are appropriate (the “Target Market Assessment”). Any person subsequently offering, selling or recommending the Shares (a “distributor”) should take into consideration the manufacturers’ Target Market Assessment; however, a distributor subject to MiFID II or the FCA Handbook Product Intervention and Product Governance Sourcebook is responsible for undertaking its own target market assessment in respect of the Shares (by either adopting or refining the manufacturers’ target market assessment) and determining appropriate distribution channels. Notwithstanding the Target Market Assessment, distributors should note that: the price of the Shares may decline, and investors could lose all or part of their investment; the Shares offer no guaranteed income and no capital protection; and an investment in the Shares is compatible only with investors who do not need a guaranteed income or capital protection, who (either alone or in conjunction with an appropriate financial or other adviser) are capable of evaluating the merits and risks of such an investment and who have sufficient resources to be able to bear any losses that may result therefrom. The Target Market Assessment is without prejudice to the requirements of any contractual, legal or regulatory selling restrictions in relation to the offering. Furthermore, it is noted that, notwithstanding the Target Market Assessment, the Managers will only procure investors who meet the criteria of professional clients and eligible counterparties.

For the avoidance of doubt, the Target Market Assessment does not constitute: (a) an assessment of suitability or appropriateness for the purposes of MiFID II or UK MiFIR; or (b) a recommendation to any investor or group of investors to invest in, or purchase, or take any other action whatsoever with respect to the Shares. Each distributor is responsible for undertaking its own target market assessment in respect of the Shares and determining appropriate distribution channels.